Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phrase "Tumor vasculature via hepatic artery embolization with local beta-radiation delivery from yttrium‑90" does not refer to a single molecular target or receptor. Instead, it describes a **therapeutic approach** for treating liver tumors—specifically hepatocellular carcinoma or metastatic disease—by targeting the **tumor’s vascular supply** through the hepatic artery. In this procedure: • The hepatic artery is catheterized and blocked using particles or beads (“embolization”), which cuts off the highly oxygenated blood that sustains most liver tumors[1][2]. • In radioembolization (“selective internal radiation therapy” or SIRT), these beads are loaded with radioactive yttrium‑90. Once lodged in the small vessels feeding the tumor, they deliver localized beta radiation directly to cancer cells while sparing most healthy tissue[2][3]. • This method exploits the fact that normal liver tissue receives most of its blood from the portal vein while tumors rely on arterial flow[1]. This is not a molecular target such as a receptor or enzyme but rather an anatomical/physiological feature exploited for therapy. The actual “target” is **the network of arteries supplying blood to malignant lesions in the liver**, not a specific molecule. Because this entry refers to an interventional radiology technique rather than a discrete biological molecule/receptor/protein/gene: • It should be flagged as incorrect if used as a canonical drug target. • There is no standard abbreviation. • No direct biomarkers exist for patient selection beyond imaging evidence of hypervascularity. • Safety concerns include post-procedure pain/fever (“postembolization syndrome”), risk of non-target embolization/injury, and potential for acute liver failure especially in those with underlying cirrhosis[4][6]. In summary: This term describes an interventional treatment strategy—not a canonical molecular drug target—and should be corrected if entered into structured databases as such.
Local delivery of beta-radiation via yttrium‑90 microspheres causes DNA damage and cell death in nearby tumor cells [2][3] Embolization blocks arterial blood flow, depriving the tumor of oxygen and nutrients [1][2][5]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor vasculature (liver tumor blood supply).